Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy
Frontiers in Pharmacology · 19.12.2025 · 16
DOI: 10.3389/fphar.2025.1738558 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.12.2025. Verfasst von Vlad Andrei Cianga und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Regional Oncology Institute, Iasi, Romania. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor–modified natural killer (CAR-NK) cells are emerging as a promising alternative to CAR-T therapies, offering advantages such as reduced toxicity, allogeneic feasibility, and flexible manufacturing. Current reviews cover NK biology and CAR engineering progress, yet lack a unified perspective that connects these advances. This review provides a novel synthesis by mapping specific tumor immune evasion mechanisms, including antigen loss, lineage plasticity, impaired antigen processing, epitope masking, and trogocytosis to corresponding next-generation CAR-NK engineering solutions. This “evasion-to-solution” framework highlights how innovations such as dual-antigen CARs, low-affinity designs, NK-specific signaling, iPSC-derived NK platforms, and multiplex gene editing directly mitigate known mechanisms that lead to therapeutic failure. By linking tumor biology to engineering strategy, this review offers a translational roadmap for the rational design of more adaptable and resilient CAR-NK therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology Department, Regional Oncology Institute, Iasi, Romania.
- Grigore T Popa University of Medicine and Pharmacy Iasi, Iasi, Romania.
- Bone Marrow Transplant Department, Regional Oncology Institute, Iasi, Romania.
Zitieren
APA
Cianga, V. A., Antohe, I., Minciună, C., & Dăscălescu, A. (2025). Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1738558
Vancouver
Cianga VA, Antohe I, Minciună C, Dăscălescu A. Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1738558
BibTeX
@article{Cianga2025,
author = {Cianga, Vlad Andrei and Antohe, Ion and Minciună, Cosmin and Dăscălescu, Angela},
title = {Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1738558}
}
EUVIMED